U.S. And Europe Hepatic Veno Occlusive Disease Treatment Market: The hepatic venous-occlusive disease also known as Sinusoidal Obstruction Syndrome (SOS) is characterized by obstruction of small veins in the liver. In this condition, the blood gets blocked in the small veins, due to the blockage of blood in small veins, blood is congested in the liver which leads to a reduction of blood flow into the liver and damages the hepatic cells. Due to the congestion, the liver gets enlarged and finally causes the liver cirrhosis. Hepatic veno-occlusive disease caused due to the long-term use of certain drugs, which can cause serious effects on liver and during bone marrow and stem cell transplantation. There is no specific treatment for the veno-occlusive disease, however, it can be treated by normalizing the blood flow in hepatic blood vessels by controlling fibrin deposition and vasculitis.
U.S. And Europe Hepatic Veno Occlusive Disease Treatment Market Outline
Increase in the prevalence of cancer diseases which require chemotherapy and radiotherapy, a rise in adoption of bone marrow and stem cell transplantation, excessive consumption of alcohol, obesity, and rise in prevalence of viral hepatitis are anticipated to fuel the hepatic veno-occlusive disease market. Moreover, increase in R&D activities for the innovation of newer drugs, lifestyle changes, and increase in healthcare expenditure are boosting the hepatic-veno occlusive disease treatment market. However, lack of specific treatment options, a high cost of treatment, and stringent regulations guidelines for drug approval might hinder the growth of U.S. And Europe Hepatic Veno Occlusive Disease Treatment Market.
Europe Hepatic Veno Occlusive Disease Treatment Market is segmented on the basis of drug class and end user
Based on the drug class, Europe Hepatic Veno Occlusive Disease Treatment Market is segmented into the following:
- Tissue Plasminogen Activators (t-PA)
- Antithrombin III (ATIII) Replacement
Based on the distribution channel, Europe Hepatic Veno Occlusive Disease Treatment Market is segmented into the following:
- Hospital Pharmacies
- Retail Pharmacies
- Online pharmacies
Europe Hepatic Veno Occlusive Disease Treatment Market is in a nascent stage, as very few drugs are available for the treatment. Healthcare professionals are majorly focussing on the alternative treatments to normalize the blood flow in hepatic small veins. Currently, market players are focusing on the development of new drugs for the treatment of hepatic veno-occlusive disease. Acquisitions and mergers, collaborations, and product launchings are the key strategies followed by companies to increase their revenue share in the hepatic veno-occlusive treatment market. For instance, in July 2014, Jazz Pharmaceuticals, Plc. inked an agreement with Sigma-Tau Pharmaceuticals, Inc. to acquire rights to Defibrotide in the in U.S. and all other countries of Americas.
Geographically, Europe Hepatic Veno Occlusive Disease Treatment Market has been segmented into U.S. and Europe. U.S. accounted for the significant share in the market owing to increase in the prevalence of various oncology diseases, the sedentary lifestyle which leads to obesity and deposition of fat in blood vessels, and rise in R&D for the innovation of newer drugs. Europe hepatic veno occlusive disease treatment market exhibiting lucrative growth owing to the approval of defibrotide by European Commission, increase in the prevalence of genetic disorders, a rise in prevalence of liver cancer in Germany, Italy, and U.K., and increase in chemotherapy and radiotherapy procedures in the region.
Some of the players in Europe Hepatic Veno Occlusive Disease Treatment Market are Jazz Pharmaceuticals Plc. (Ireland), Novartis AG (Switzerland), and Norgine Pharmaceuticals Ltd. (U.K.) to name a few.
- In March 2016, Jaz Pharmaceuticals Plc. received FDA approval for Defitelio used in the treatment of hepatic veno-occlusive disease treatment
- The report provides granular level information about the market size, regional market share, and forecast from 2017-2023
- The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments, and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario